Investors

2017 News

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
04/18/17Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results
COPENHAGEN, Denmark, April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016. Net income for the fourth quarter December 31, 2016 was $9.6 million while net loss for the year ended December 31, 2016 was $33.3 million, or $0.20 and $(0.71) per diluted share, respectively. On a non-GAAP basis, after removing the effect of non-cash income and expense items, our... 
Printer Friendly Version
03/31/17Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
COPENHAGEN, Denmark, March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that it intends to file an appeal challenging today’s decision by the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) in Pat... 
Printer Friendly Version
03/01/17Forward Pharma Appoints Claus Bo Svendsen as Chief Executive Officer and Plans to Reorganize to Reduce Burn Rate Following the Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen, M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017. He previously held the position of Executive Vice President at the Company. Dr. Svendsen succeeds Peder M. Andersen, M.D., who has led the Company since 2012. Dr. Andersen will retain his role as Chief Operating Officer and serve until Septe... 
Printer Friendly Version
02/09/17Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen
COPENHAGEN, Denmark, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned subsidiaries of Biogen Inc. and certain other parties (the “License Agreement”). On January 17, 2017 Forward entered into the License Agreement subject to the approval of its shareholders and certain... 
Printer Friendly Version
02/01/17Forward Pharma Announces Results of Extraordinary General Meeting
Forward obtains shareholder approval for Settlement and License Agreement with Biogen COPENHAGEN, Denmark, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that, at an extraordinary general meeting of its shareholders held on February 1, 2017 (the “Extraordinary General Meeting”), the requisite two-thirds majority of the votes cast as well as the share capital represented at the Extraordinary General Meeting approved the entry into a Settle... 
Printer Friendly Version
01/17/17Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory approvals COPENHAGEN, Denmark, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has entered into a binding agreement with two wholly owne... 
Printer Friendly Version